2022 World Conference on Lung Cancer (ePosters)-EP08.02-002. Aumolertinib in the Treatment of Activated EGFR Mutation Advanced NSCLC Patients with Interstitial Pneumonia

EP08.02-002. Aumolertinib in the Treatment of Activated EGFR Mutation Advanced NSCLC Patients with Interstitial Pneumonia

Back to course

Pdf Summary

Interstitial pneumonia is a rare but serious complication in patients receiving treatment with EGFR-TKIs, with a high mortality rate. Currently, there is uncertainty about whether EGFR-TKIs can be reintroduced after interstitial inflammation subsides. Aumolertinib, a third-generation EGFR-TKI, has shown promising efficacy and safety in NSCLC patients with EGFR-sensitive mutations, with a low incidence of interstitial lung disease. Two studies, APOLLO and AENEAS, reported no cases of interstitial lung disease with aumolertinib. However, the mechanism behind this needs further investigation. <br /><br />The case study presented an 81-year-old male patient with NSCLC who had undergone various treatments, including surgery, chemotherapy, first and third-generation EGFR-TKIs, and aumolertinib re-challenge. The patient initially had a partial remission with gefitinib, but due to recurrent drug-related liver injury, he switched to icotinib. After disease progression with T790M mutation, he was switched to osimertinib, which resulted in partial remission but also developed interstitial pneumonia. The patient then switched to aumolertinib, which showed stable efficacy without recurrence of interstitial pneumonia.<br /><br />Discontinuing osimertinib could have negatively impacted the patient's prognosis, and chemotherapy may have affected his quality of life. Therefore, aumolertinib was chosen as a follow-up treatment, providing a survival benefit and avoiding interstitial pneumonia. This case study suggests a new treatment option for patients who develop interstitial lung disease after EGFR-TKI therapy.<br /><br />The study acknowledges the investigators, nurses, and support staff who treated and cared for the patients. It also expresses gratitude to the patients and their families who participated in the trial.

Asset Subtitle

Jie Tan

Meta Tag

Speaker Jie Tan

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

interstitial pneumonia

EGFR-TKIs

mortality rate

reintroduction of EGFR-TKIs

Aumolertinib

NSCLC patients

EGFR-sensitive mutations

interstitial lung disease

APOLLO study

AENEAS study